Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Subscribe To Our Newsletter & Stay Updated
